000212102 001__ 212102
000212102 005__ 20181203024013.0
000212102 0247_ $$2doi$$a10.1021/acs.molpharmaceut.5b00417
000212102 022__ $$a1543-8384
000212102 02470 $$2ISI$$a000359096100049
000212102 037__ $$aARTICLE
000212102 245__ $$aAntiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains
000212102 260__ $$aWashington$$bAmer Chemical Soc$$c2015
000212102 269__ $$a2015
000212102 300__ $$a8
000212102 336__ $$aJournal Articles
000212102 520__ $$aTwo bifunctional ruthenium(II)-p-cymene complexes with perfluorinated side chains, attached via pyridine ligands, have been evaluated in a series of in vitro and in vivo assays. Their effects on human endothelial (ECRF24 and HUVEC) cells, noncancerous human embryonic kidney (HEK-293) cells, and various human tumor cells were investigated. The complex with the shorter chain, 1, inhibits the proliferation of the tumor cell lines and ECRF24, whereas 2 selectively inhibits ECRF24 and HUVEC proliferation. Neither inhibits the migration of ECRF24 cells whereas both compounds inhibit sprout formation in HUVEC cells. Using three preclinical models, i.e., vasculature formation in the chorioallantoic membrane (CAM) of the chicken embryo, human A2780 ovarian carcinoma tumors xenografted on the CAM, and human LS174T colorectal adenocarcinoma tumors grown in athymic mice, the angiostatic and anticancer activities of these two complexes were studied. Overall, 1 inhibited tumor growth predominantly through an anticancer effect whereas 2 inhibited tumor growth predominately via an antiangiogenic mechanism.
000212102 6531_ $$aantiangiogenesis
000212102 6531_ $$abioorganometallic chemistry
000212102 6531_ $$aCAM model
000212102 6531_ $$acolorectal adenocarcinoma
000212102 6531_ $$aovarian carcinoma
000212102 6531_ $$aruthenium(II)-arene complexes
000212102 6531_ $$afluorine chemistry
000212102 700__ $$0245027$$aNowak-Sliwinska, Patrycja$$g168504$$uVrije Univ Amsterdam Med Ctr, Dept Med Oncol, Angiogenesis Lab, NL-1007 MB Amsterdam, Netherlands
000212102 700__ $$0244594$$aClavel, Catherine M.$$g192123
000212102 700__ $$0245325$$aPaunescu, Emilia$$g211976
000212102 700__ $$aTe Winkel, Marije T.
000212102 700__ $$aGriffioen, Arjan W.$$uVrije Univ Amsterdam Med Ctr, Dept Med Oncol, Angiogenesis Lab, NL-1007 MB Amsterdam, Netherlands
000212102 700__ $$0240015$$aDyson, Paul J.$$g149418
000212102 773__ $$j12$$k8$$q3089-3096$$tMolecular Pharmaceutics
000212102 909C0 $$0252010$$pLCOM$$xU9
000212102 909CO $$ooai:infoscience.tind.io:212102$$pSB$$particle
000212102 917Z8 $$x135992
000212102 937__ $$aEPFL-ARTICLE-212102
000212102 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000212102 980__ $$aARTICLE